Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{191434,
        author = {Miss. Zeemi Dadhaniya and Prof. Aarti Bhetariya},
        title = {Anti cancer drugs: Current challenges And Future Direction},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {6355-6360},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=191434},
        abstract = {Cancer is a complex disease that has evolved in understanding from early surgical and radiation approaches to today’s molecular classification and precision therapies. Current treatments including targeted drugs, immunotherapy, nanomedicine, and emerging stem cell based strategies have significantly improved the results but still have serious obstacles in clinical translation, such as biological barriers, toxicity and safety issues, and regulatory difficulties. The use of drugs such as doxorubicin not only improves the efficacy but also drawbacks of traditional chemotherapy because of such side effects as cardiotoxicity. Recent progress  of targeted delivery and immunotherapy have great benefits of specificity and less side effects. The future direction are on next generation therapeutics, such as genome-directed therapeutic approach, novel nanocarrier and sustainable development of drugs to realize safer, more effective and accessible to global cancer care.},
        keywords = {Cancer, Nanomedicine , Immunotherapy, Stem cell therapy, Doxorubicin, Immunotherapy, Targeted Therapy, cardiotoxicity,  Nanocarrier.},
        month = {January},
        }